Key points from article :
SENS Research Foundation hosted a pitch day at J.P. Morgan Healthcare conference.
Kimera Labs exosomes stimulate growth signaling characteristic of embryonic development.
Viscient Biosciences works on 3D bioprinting of human tissues for drug discovery and validation.
OncoSenX targets p53 gene (via fusogenic lipid nanoparticle platform) to selectively destroy cancer cells.
Underdog Pharmaceuticals works on removal of 7-ketocholesterol persistent metabolic waste.
Turn.bio using cellular reprogramming to reverse the epigenetic changes and loss of cell function.
Gero using machine learning to speed up identification of therapeutics that might influence aging.
Nemalife automates C. elegans studies with microfluidic chips - making studies more cost-effective.
AgeX Therapeutics subsidiary Reverse Bioengineering also working on cell reprogramming.
Volumetric uses advanced 3D bioprinting to incorporate blood vessel networks in printed tissue.
712 North is focused on small molecule manipulation of mitochondrial pathways around OPA1.
Qalytude service provides easy online process to obtain prescription anti-ageing medications.
Oisin Biotechnologies is targeting cellular senescence via cells expressing p16.
Leucadia Therapeutics improves drainage of cerebrospinal fluid to reduce risk of Alzheimer's disease,
Repair Biotechnologies working on regeneration of the thymus to address immunosenescence.
Retrotope carries out human studies of treatment with deuterium loaded fatty acids.
Revel Pharmaceuticals aims to commercialize glucosepane cross-link breakers.
Maia Biotechnology target telomeres to suppress tumor growth.
A stunning array of ideas - any of which on their own would be truly revolutionary
